Pharvaris N.V. (PHVS)
$18.55
+0.05 (+0.27%)
Rating:
Recommendation:
-
| Symbol | PHVS |
|---|---|
| Price | $18.55 |
| Beta | -3.816 |
| Volume Avg. | 0.05M |
| Market Cap | 757.894M |
| Shares () | - |
| 52 Week Range | 1.77-26.86 |
| 1y Target Est | - |
| DCF Unlevered | PHVS DCF -> | |
|---|---|---|
| DCF Levered | PHVS LDCF -> | |
| ROE | -43.67% | Strong Sell |
| ROA | -36.67% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 0.19% | Neutral |
| P/E | -7.96 | Strong Sell |
| P/B | 4.16 | Strong Buy |
Latest PHVS news
About
Download (Excel)Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA
Healthcare
Biotechnology
NASDAQ Global Select
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.